Last reviewed · How we verify
Tis-U-Sol
Tis-U-Sol is a tissue-specific drug delivery system designed to enhance drug penetration and retention in target tissues.
Tis-U-Sol is a tissue-specific drug delivery system designed to enhance drug penetration and retention in target tissues. Used for Cancer (specific indication not publicly detailed).
At a glance
| Generic name | Tis-U-Sol |
|---|---|
| Sponsor | Affiliated Cancer Hospital & Institute of Guangzhou Medical University |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Tis-U-Sol appears to be a formulation or delivery technology platform rather than a traditional small-molecule or biologic drug. It is developed by an oncology-focused institution and likely functions as an adjunctive or enabling technology to improve therapeutic agent distribution to tumor tissues or other target sites. Specific mechanistic details regarding its molecular targets or active components are not publicly well-characterized.
Approved indications
- Cancer (specific indication not publicly detailed)
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tis-U-Sol CI brief — competitive landscape report
- Tis-U-Sol updates RSS · CI watch RSS
- Affiliated Cancer Hospital & Institute of Guangzhou Medical University portfolio CI